Chemours Company (The) (NYSE:CC) – Stock analysts at Jefferies Group boosted their FY2020 EPS estimates for shares of Chemours Company (The) in a note issued to investors on Friday. Jefferies Group analyst L. Alexander now expects that the specialty chemicals company will earn $5.60 per share for the year, up from their prior forecast of $5.20. Jefferies Group currently has a “Buy” rating and a $60.00 target price on the stock.

Chemours Company (The) (NYSE:CC) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm posted $0.27 earnings per share. The business’s revenue was up 14.8% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/21/fy2020-eps-estimates-for-chemours-company-the-lifted-by-jefferies-group-cc.html.

Several other equities analysts also recently weighed in on the company. BidaskClub downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Argus reiterated a “buy” rating and set a $55.00 target price (up from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th. UBS AG upgraded Chemours Company (The) from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $36.00 to $50.00 in a report on Monday, August 7th. J P Morgan Chase & Co raised their price objective on Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a report on Friday, August 4th. Finally, Citigroup Inc. raised their price objective on Chemours Company (The) from $45.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $51.50.

Chemours Company (NYSE CC) traded up 1.24% during midday trading on Monday, reaching $46.65. 100,778 shares of the company’s stock traded hands. Chemours Company has a 52-week low of $12.16 and a 52-week high of $51.51. The stock has a market cap of $8.62 billion, a P/E ratio of 30.53 and a beta of 3.63. The company’s 50-day moving average price is $45.01 and its 200-day moving average price is $38.80.

Several institutional investors have recently added to or reduced their stakes in CC. Archford Capital Strategies LLC purchased a new position in Chemours Company (The) during the second quarter worth approximately $1,178,000. Cookson Peirce & Co. Inc. purchased a new position in Chemours Company (The) during the second quarter worth approximately $2,703,000. Public Employees Retirement System of Ohio increased its position in Chemours Company (The) by 306.4% in the second quarter. Public Employees Retirement System of Ohio now owns 98,590 shares of the specialty chemicals company’s stock worth $3,739,000 after buying an additional 74,329 shares during the period. Koch Industries Inc. purchased a new position in Chemours Company (The) during the second quarter worth approximately $704,000. Finally, 1st Global Advisors Inc. purchased a new position in Chemours Company (The) during the second quarter worth approximately $596,000. Institutional investors own 76.51% of the company’s stock.

In other news, insider E Bryan Snell sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $46.24, for a total value of $462,400.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Amy Trojanowski sold 2,500 shares of the firm’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $46.03, for a total value of $115,075.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,536 shares of company stock worth $1,365,946. Company insiders own 1.14% of the company’s stock.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 17th will be issued a $0.03 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.26%. Chemours Company (The)’s dividend payout ratio (DPR) is 8.11%.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Earnings History and Estimates for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.